INDEX // 06
Frequently asked questions about the blend
Twenty-five questions on BPC-157 TB-500 — definition, mechanism, evidence, dosing, safety, and access — each answered directly and cited to a study where the answer is quantitative.
Evidence and the data gap
The state of the evidence on the BPC-157 TB-500 blend, in three questions: what the latest research shows, what reviewers conclude, and whether the combination has been trialed in humans.
What is the latest research on BPC-157 and TB-500?
The most defensible recent literature (2024-2026) is review-level: a 2025 systematic review of BPC-157 (36 studies, 1 human, no clinical safety data, no TB-500 mention) [9], a 2026 Sports Medicine review of unapproved musculoskeletal peptides [10], and recent BPC-157 mechanism and rat-recovery studies [11]. None studied the combination.
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: three small BPC-157 pilots, and the human data labeled "TB-500" are for full-length Thymosin Beta-4, not the heptapeptide [16].
What do doctors and reviews say about the BPC-157 + TB-500 blend?
Recent narrative and systematic reviews describe promising animal-model tissue repair but stress that human safety data are scarce, the evidence is low-tier (level IV-V), and both peptides should be treated as investigational and used with caution given non-regulated availability [9][10][12].
Definition and naming
What the BPC-157 TB-500 blend is, what it contains, and how the two peptides differ.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 with TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product — the two are distinct synthetic peptides co-marketed under one label.
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide and the cytoprotective/angiogenic component [1]. TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4, the cytoskeletal/cell-migration component [3]. The blend pairs the two.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-mer gastric-juice-derived peptide acting locally via VEGFR2 and eNOS [2]; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [3]. Different size, origin, and mechanism, paired for complementary effects.
What it is studied for
Each repair claim traces to single-compound, mostly animal data — never a combination trial.
What is the BPC-157 and TB-500 blend used for in research?
It is studied in preclinical, mostly rodent, tissue-repair models: BPC-157 in tendon, ligament, and wound work [1]; TB-500/Thymosin Beta-4 in migration, re-epithelialization, and angiogenesis [5]. No human combination efficacy is established.
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In animal models, BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1]. These are preclinical, single-compound findings; the blend's effect in humans is unproven.
Does BPC-157 and TB-500 help muscle tears and recovery?
Recovery interest rests on preclinical work, including a 2025 rat study of BPC-157 after surgical quadriceps detachment for muscle-to-bone reattachment [11]. No controlled human study supports muscle-recovery claims for the blend.
Does the BPC-157 TB-500 blend help wound healing?
Thymosin Beta-4 accelerated re-epithelialization, collagen deposition, and migration in animal wound models, and BPC-157 showed broad cytoprotection [5]. These are preclinical, single-compound findings; the blend's wound-healing effect in humans is unproven.
Mechanism and synergy
How each peptide works, and what the synergy claim does and does not rest on.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale pairs BPC-157's local cytoprotective/pro-angiogenic signal [2] with TB-500's actin-sequestration/cell-migration signal [3] as complementary mechanisms. This synergy is a theoretical extrapolation, not a finding from any controlled combination study.
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. A 2025 systematic review of BPC-157 (36 studies, only 1 human) makes no mention of TB-500 or combination use [9], and no peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together.
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1; crystallography of a Thymosin Beta-4-actin complex showed it sequesters the monomer by capping both ends, regulating the cytoskeletal dynamics that drive cell migration [3].
How does BPC-157 work compared to TB-500?
BPC-157 acts through a local cytoprotective/pro-angiogenic route — VEGFR2-Akt-eNOS up-regulation [2]; TB-500 acts through intracellular actin sequestration governing cell migration [3]. The two are described as complementary but largely non-overlapping.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
BPC-157 is pro-angiogenic via VEGFR2 up-regulation and internalization with downstream Akt-eNOS signaling [2]; TB-500/Thymosin Beta-4 promotes angiogenesis through endothelial migration [5]. Both are reported in animal and in-vitro models.
Dosing, half-life, and reconstitution
Research-context dosing facts only — no human guidance, no validated blend protocol.
What is the half-life of BPC-157 and TB-500?
A rat/dog PK study reported BPC-157's elimination half-life as under 30 minutes [6]; no validated human half-life exists for either constituent at research doses, and none for the blend [16].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [16]; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed.
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis [16]. Underlying animal studies used per-body-weight doses that are not human guidance [1][7].
How do you cycle BPC-157 and TB-500?
Community "loading then maintenance" cycling protocols have no controlled-trial basis [16]. No validated blend schedule exists; described findings are preclinical and dosed per body weight in animals [7].
Side effects and safety considerations
On side effects and safety considerations: human safety data are limited to the individual constituents, and one signal warrants explicit framing.
What are the side effects of BPC-157 and TB-500?
Human safety data are limited to the individual constituents (full-length Thymosin Beta-4 was well tolerated in IV Phase 1 studies) [16]; the blend's combination safety is unproven, and recent reviews note potential for serious harm with unapproved peptides [10].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [5]. This is a safety consideration, not a demonstrated outcome in blend users.
Regulatory and legal status
Approval, anti-doping, and FDA 503A status — answered from the audited record. Full detail is on Wolverine legal status and FDA 503A category.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and the blend has no approved indication [19]. Both carry WADA prohibited status — BPC-157 under the S0 non-approved-substances category, and TB-500/Thymosin Beta-4 under prohibited peptide and growth-factor categories [24].
Is the Wolverine (BPC-157 + TB-500) blend legal?
Neither constituent is an approved drug and the blend has no approved indication; it is distributed for research use, and both are currently FDA Category 2 bulk substances not eligible for routine 503A compounding [19]. Both are on the July 23-24, 2026 PCAC agenda being considered for the 503A bulks list — a scheduled review, not a decision [17].
Can you get BPC-157 from a compounding pharmacy?
Not through routine 503A compounding while its current status stands. The FDA placed BPC-157 in Category 2 — bulk substances that may present significant safety risks — effective with the September 29, 2023 list update [19]. It is on the July 2026 PCAC agenda for evaluation, which is not a listing decision [17].
What is the FDA 503A status of the Wolverine blend?
Both components are FDA Category 2 for 503A compounding (effective September 29, 2023), identified as raising significant safety risks and not afforded enforcement discretion [19]. Both appear on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A Bulks List [17].